{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,19]],"date-time":"2026-02-19T04:46:59Z","timestamp":1771476419072,"version":"3.50.1"},"reference-count":14,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2023,4,1]],"date-time":"2023-04-01T00:00:00Z","timestamp":1680307200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,4,1]],"date-time":"2023-04-01T00:00:00Z","timestamp":1680307200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,4,1]],"date-time":"2023-04-01T00:00:00Z","timestamp":1680307200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2023,4,1]],"date-time":"2023-04-01T00:00:00Z","timestamp":1680307200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2023,4,1]],"date-time":"2023-04-01T00:00:00Z","timestamp":1680307200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2023,4,1]],"date-time":"2023-04-01T00:00:00Z","timestamp":1680307200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2023,4,1]],"date-time":"2023-04-01T00:00:00Z","timestamp":1680307200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","trasci.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Transfusion and Apheresis Science"],"published-print":{"date-parts":[[2023,4]]},"DOI":"10.1016\/j.transci.2023.103682","type":"journal-article","created":{"date-parts":[[2023,3,1]],"date-time":"2023-03-01T02:16:51Z","timestamp":1677637011000},"page":"103682","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"title":["Thrombotic thrombocytopenic purpura in caplacizumab era \u2013 An individualized approach"],"prefix":"10.1016","volume":"62","author":[{"given":"Ravi","family":"Sarode","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"10","key":"10.1016\/j.transci.2023.103682_bib1","doi-asserted-by":"crossref","first-page":"2496","DOI":"10.1111\/jth.15010","article-title":"ISTH guidelines for treating thrombotic thrombocytopenic purpura","volume":"18","author":"Zheng","year":"2020","journal-title":"J Thromb Haemost"},{"issue":"5","key":"10.1016\/j.transci.2023.103682_bib2","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1111\/bjh.18127","article-title":"Mind and matter: the neurological complications of thrombotic thrombocytopenic purpura","volume":"197","author":"Shaw","year":"2022","journal-title":"Br J Haematol"},{"issue":"3","key":"10.1016\/j.transci.2023.103682_bib3","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1111\/jth.12114","article-title":"Rituximab for thrombotic thrombocytopenic purpura: benefit of early administration during acute episodes and use of prophylaxis to prevent relapse","volume":"11","author":"Westwood","year":"2013","journal-title":"J Thromb Haemost"},{"key":"10.1016\/j.transci.2023.103682_bib4","doi-asserted-by":"crossref","first-page":"3603","DOI":"10.1182\/blood-2012-04-420943","article-title":"Evaluation of efficacy and safety of the anti-VWF nanobody ALX-0681 in a preclinical baboon model of acquired thrombotic thrombocytopenic purpura","volume":"120","author":"Callewaert","year":"2012","journal-title":"Blood"},{"issue":"6","key":"10.1016\/j.transci.2023.103682_bib5","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1056\/NEJMoa1505533","article-title":"Caplacizumab for acquired thrombotic thrombocytopenic purpura","volume":"374","author":"Peyvandi","year":"2016","journal-title":"N Engl J Med"},{"issue":"4","key":"10.1016\/j.transci.2023.103682_bib6","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1056\/NEJMoa1806311","article-title":"aplacizumab treatment for acquired thrombotic thrombocytopenic purpura","volume":"380","author":"Scully","year":"2019","journal-title":"N Engl J Med"},{"issue":"1","key":"10.1016\/j.transci.2023.103682_bib7","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1182\/hematology.2022000412","article-title":"Evidence-based minireview: should caplacizumab be used routinely in unselected patients with immune thrombotic thrombocytopenic purpura?","volume":"2022","author":"Goshua","year":"2022","journal-title":"Hematol Am Soc Hematol Educ Program"},{"issue":"12","key":"10.1016\/j.transci.2023.103682_bib8","doi-asserted-by":"crossref","first-page":"3051","DOI":"10.1007\/s00277-020-04260-7","article-title":"Caplacizumab: frequent local skin reactions","volume":"100","author":"Kaufeld","year":"2021","journal-title":"Ann Hematol"},{"issue":"3","key":"10.1016\/j.transci.2023.103682_bib9","doi-asserted-by":"crossref","first-page":"484","DOI":"10.1080\/09537104.2021.1922883","article-title":"Fatal cerebral hemorrhage in a patient with thrombotic thrombocytopenic purpura with a normal platelet count during treatment with caplacizumab","volume":"33","author":"Ditzel","year":"2022","journal-title":"Platelets"},{"issue":"8","key":"10.1016\/j.transci.2023.103682_bib10","doi-asserted-by":"crossref","first-page":"1922","DOI":"10.1111\/jth.15363","article-title":"Intracranial hemorrhage in immune thrombotic thrombocytopenic purpura treated with caplacizumab","volume":"19","author":"Schofield","year":"2021","journal-title":"J Thromb Haemost"},{"issue":"4","key":"10.1016\/j.transci.2023.103682_bib11","doi-asserted-by":"crossref","first-page":"951","DOI":"10.1111\/jth.15637","article-title":"Alternate-day dosing of caplacizumab for immune-mediated thrombotic thrombocytopenic purpura","volume":"20","author":"K\u00fchne","year":"2022","journal-title":"Thromb Haemost"},{"issue":"6","key":"10.1016\/j.transci.2023.103682_bib12","doi-asserted-by":"crossref","first-page":"1157","DOI":"10.1182\/blood-2012-02-412197","article-title":"Circulating DNA, and myeloperoxidase indicate disease activity in patients with thrombotic microangiopathies","volume":"120","author":"Fuchs","year":"2012","journal-title":"Blood"},{"issue":"9","key":"10.1016\/j.transci.2023.103682_bib13","doi-asserted-by":"crossref","first-page":"903","DOI":"10.1182\/blood-2018-02-791533","article-title":"The role of ADAMTS13 testing in the diagnosis and management of thrombotic microangiopathies and thrombosis","volume":"132","author":"Masias","year":"2018","journal-title":"Blood"},{"issue":"4","key":"10.1016\/j.transci.2023.103682_bib14","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1016\/j.tmrv.2022.09.001","article-title":"Plasma cell directed therapy for immune thrombotic thrombocytopenic purpura (iTTP)","volume":"36","author":"Chen","year":"2022","journal-title":"Transfus Med Rev"}],"container-title":["Transfusion and Apheresis Science"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1473050223000502?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1473050223000502?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,26]],"date-time":"2025-10-26T08:55:11Z","timestamp":1761468911000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1473050223000502"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,4]]},"references-count":14,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2023,4]]}},"alternative-id":["S1473050223000502"],"URL":"https:\/\/doi.org\/10.1016\/j.transci.2023.103682","relation":{},"ISSN":["1473-0502"],"issn-type":[{"value":"1473-0502","type":"print"}],"subject":[],"published":{"date-parts":[[2023,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Thrombotic thrombocytopenic purpura in caplacizumab era \u2013 An individualized approach","name":"articletitle","label":"Article Title"},{"value":"Transfusion and Apheresis Science","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.transci.2023.103682","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"103682"}}